4 ms·
The process that patients go through when participating in a medical trial of psilocybin is so different than the typical recreational setting that the rest of
by spuz 6y ago
The process that patients go through when participating in a medical trial of psilocybin is so different than the typical recreational setting that the rest of us experience these drugs. They do everything they can to make sure the patient is well prepared and has the minimum chance of having a bad trip.
However, every time I read about studies into psychedelics, I only ever hear about the upsides and not the potential downsides. I went through a similar experience to you - although not as severe. I had anxiety for about 3 years after my bad trip which luckily gradually reduced over time.
What worries me is that the more these drugs gain credibility in the medical field the more likely it is that depressed kids are going to self-medicate and given the ability of these drugs to multiply the user's existing anxieties, they should be the last people who should be experimenting and self-medicating with them.
- Trasmatta 6y agoI also had severe, lasting anxiety after a couple of bad trips. I will never use again unless I get the opportunity to do so in a therapeutic setting with trained professionals. There is tremendous potential for good with these substances, but they have some real risks.
- PragmaticPulp 6y ago> The process that patients go through when participating in a medical trial of psilocybin is so different than the typical recreational setting that the rest of us experience these drugs. They do everything they can to make sure the patient is well prepared and has the minimum chance of having a bad trip. Not just this, but they surround the sessions with intense therapy. They're not just giving people psychedelics and keeping them calm. Look up the MAPS (a foundation for psychedelic research) protocol. People are given a series of intense therapy sessions, only some of which involve psychedelics. Sadly, many of the studies fail to have an active control group. That is, they aren't comparing therapy + psychedelics to therapy alone. That's a major pitfall in the current research. And unfortunately, the therapy component of the research is lost in most internet headlines and articles. People are walking away with the impression that psychedelics are inherently anti-depressant compounds, when the reality is that they're being researched as adjuncts to intense therapy.